Eduardo Pimenta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5519220/publications.pdf

Version: 2024-02-01

172207 133063 3,603 63 29 59 citations h-index g-index papers 66 66 66 3330 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension, 2009, 54, 475-481.	1.3	474
2	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	1.8	310
3	Characterization of Resistant Hypertension <subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle> . Archives of Internal Medicine, 2008, 168, 1159.	4.3	254
4	Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension, 2010, 24, 532-537.	1.0	252
5	Resistant Hypertension. Circulation, 2012, 125, 1594-1596.	1.6	173
6	Factors Affecting the Aldosterone/Renin Ratio. Hormone and Metabolic Research, 2012, 44, 170-176.	0.7	164
7	Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism. Hypertension, 2010, 55, 1137-1142.	1.3	137
8	Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension. Journal of Clinical Sleep Medicine, 2010, 06, 363-368.	1.4	123
9	Diagnosis and management of primary aldosteronism: An updated review. Annals of Medicine, 2013, 45, 375-383.	1.5	111
10	Quality of Life in Patients with Bilateral Primary Aldosteronism before and during Treatment with Spironolactone and/or Amiloride, Including a Comparison with Our Previously Published Results in Those with Unilateral Disease Treated Surgically. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2904-2911.	1.8	90
11	Are Women More at Risk of False-Positive Primary Aldosteronism Screening and Unnecessary Suppression Testing than Men?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E340-E346.	1.8	86
12	Effect of Contraceptives on Aldosterone/Renin Ratio May Vary According to the Components of Contraceptive, Renin Assay Method, and Possibly Route of Administration. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1797-1804.	1.8	80
13	Hypertension in women. Hypertension Research, 2012, 35, 148-152.	1.5	73
14	Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2813-2820.	1.8	72
15	Prehypertension: epidemiology, consequences and treatment. Nature Reviews Nephrology, 2010, 6, 21-30.	4.1	71
16	Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension. Hypertension, 2008, 51, 339-344.	1.3	69
17	Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. Journal of Human Hypertension, 2011, 25, 532-538.	1.0	68
18	Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. Journal of Clinical Sleep Medicine, 2010, 6, 363-8.	1.4	66

#	Article	IF	Citations
19	Laboratory investigation of primary aldosteronism. Clinical Biochemist Reviews, 2010, 31, 39-56.	3.3	63
20	Increased Dietary Sodium Is Related to Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension and Hyperaldosteronism. Chest, 2013, 143, 978-983.	0.4	61
21	Sleep Apnea, Aldosterone, and Resistant Hypertension. Progress in Cardiovascular Diseases, 2009, 51, 371-380.	1.6	59
22	Management of hypertension in the elderly. Nature Reviews Cardiology, 2012, 9, 286-296.	6.1	54
23	Aldosterone and Cardiovascular Disease. Current Problems in Cardiology, 2009, 34, 51-84.	1.1	51
24	Resistant hypertension and aldosteronism. Current Hypertension Reports, 2007, 9, 353-359.	1.5	46
25	Effect of Atenolol on Aldosterone/Renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male Volunteers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3201-3206.	1.8	44
26	Mechanisms and Treatment of Resistant Hypertension. Journal of Clinical Hypertension, 2008, 10, 239-244.	1.0	42
27	Effects of Two Selective Serotonin Reuptake Inhibitor Antidepressants, Sertraline and Escitalopram, on Aldosterone/Renin Ratio in Normotensive Depressed Male Patients. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1039-1045.	1.8	41
28	Aldosterone excess and resistance to 24-h blood pressure control. Journal of Hypertension, 2007, 25, 2131-2137.	0.3	36
29	Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan – amlodipine combination. Vascular Health and Risk Management, 2008, Volume 4, 653-654.	1.0	31
30	Gene Variation in Resistant Hypertension: Multilocus Analysis of the Angiotensin 1-Converting Enzyme, Angiotensinogen, and Endothelial Nitric Oxide Synthase Genes. DNA and Cell Biology, 2011, 30, 555-564.	0.9	30
31	Adverse Cardiovascular Outcomes of Corticosteroid Excess. Endocrinology, 2012, 153, 5137-5142.	1.4	30
32	Treatment of hypertension in the emergency department. Journal of the American Society of Hypertension, 2011, 5, 366-377.	2.3	29
33	Primary Aldosteronism: Diagnosis and Treatment. Journal of Clinical Hypertension, 2006, 8, 887-893.	1.0	27
34	Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. Journal of Hypertension, 2013, 31, 2005-2009.	0.3	27
35	I posicionamento brasileiro sobre hipertensão arterial resistente. Arquivos Brasileiros De Cardiologia, 2012, 99, 576-585.	0.3	27
36	Aldosterone Excess or Escape: Treating Resistant Hypertension. Journal of Clinical Hypertension, 2009, 11, 245-252.	1.0	25

#	Article	IF	Citations
37	Familial or Genetic Primary Aldosteronism and Gordon Syndrome. Endocrinology and Metabolism Clinics of North America, 2011, 40, 343-368.	1.2	25
38	Aldosterone, Dietary Salt, and Renal Disease. Hypertension, 2006, 48, 209-210.	1.3	18
39	Aldosterone and Metabolic Dysfunction. Hypertension, 2009, 53, 585-586.	1.3	18
40	Efficacy of an Olmesartan Medoxomil–Based Treatment Algorithm in Patients Stratified by Age, Race, or Sex. Journal of Clinical Hypertension, 2010, 12, 3-13.	1.0	18
41	Salt and Aldosterone. Hypertension, 2010, 56, 804-805.	1.3	15
42	Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Therapeutics and Clinical Risk Management, 2009, 5, 459.	0.9	15
43	Treatment of resistant hypertension. Journal of Hypertension, 2010, 28, 2194-2195.	0.3	14
44	Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study. Journal of Clinical Medicine Research, 2016, 8, 836-839.	0.6	14
45	Mecanismos e tratamento da hipertens $ ilde{A}$ £o arterial refrat $ ilde{A}$ ¡ria. Arquivos Brasileiros De Cardiologia, 2007, 88, 683-692.	0.3	13
46	Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering?. Cardiology Clinics, 2008, 26, 527-535.	0.9	11
47	SÃndrome metabólica em pacientes submetidos à cirurgia de revascularização miocárdica: prevalência e marcador de morbi-mortalidade no perÃodo intra-hospitalar e após 30 dias. Arquivos Brasileiros De Cardiologia, 2007, 88, 413-417.	0.3	10
48	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. Current Hypertension Reports, 2016, 18, 25.	1.5	6
49	Hyperreninemic hypertension following presumed abdominal trauma. Nature Reviews Nephrology, 2011, 7, 730-734.	4.1	5
50	Renal Sympathetic Denervation for Treatment of Hypertension. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 127-135.	0.4	5
51	Uncontrolled hypertension: beyond pharmacological treatment. Hypertension Research, 2009, 32, 729-731.	1.5	4
52	Renin Angiotensin System Blockage Associates with Insertion/Deletion Polymorphism of Angiotensin-Converting Enzyme in Patients with Hypertensive Emergency. DNA and Cell Biology, 2013, 32, 541-548.	0.9	4
53	Increasing adherence: is that enough?. Hypertension Research, 2010, 33, 411-413.	1.5	2
54	What is new in the management of resistant hypertension?. Therapy: Open Access in Clinical Medicine, 2011, 8, 261-273.	0.2	2

#	Article	IF	CITATIONS
55	Hypertensive crisis. Journal of Hypertension, 2012, 30, 882-883.	0.3	2
56	Hemarthrosis of the knees following streptokinase therapy for acute myocardial infarction. Arquivos Brasileiros De Cardiologia, 2003, 80, 641-642.	0.3	1
57	Sevikar®: combination therapy for the treatment of hypertension. Advances in Therapy, 2009, 26, 1-11.	1.3	1
58	Should we send our kids to the gym?. Hypertension Research, 2010, 33, 880-882.	1.5	1
59	Clinical trials report. Current Hypertension Reports, 2008, 10, 213-215.	1.5	O
60	Is There a Place on the Shelf for Aliskiren?. Current Cardiovascular Risk Reports, 2010, 4, 264-270.	0.8	O
61	Response to "Effective―Plasma Renin Activity: A Derived Measure for Assessing Residual Plasma Renin Activity in Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Hypertension, 2010, 55, .	1.3	0
62	Obstructive Sleep Apnea and Sodium Intake: Response. Chest, 2013, 144, 720.	0.4	0
63	Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective. , 2008, 118, 508-12.		O